Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

NCT03144687 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03144687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03144687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2018
Completion date
June 1, 2021
Enrollment
23 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)